Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
The company said brelovitug met the Phase 3 primary endpoint at Week 24 in both dose arms. Mirum also reported 48-week Phase 2b data showing deeper viral suppression and no new safety signals.
Mirum Pharmaceuticals said topline Phase 3 AZURE-1 results for brelovitug are due Sept. 28. The company also plans to report 48-week Phase 2b results and hold an investor call at 8:30 a.m. ET.